Alnylam Pharmaceuticals, Inc.
Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Last updated:
Abstract:
The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.
Status:
Grant
Type:
Utility
Filling date:
4 Nov 2019
Issue date:
20 Sep 2022